MBX Biosciences, Inc. Operating Cash Flow
MBX Biosciences, Inc. (MBX) reported Operating Cash Flow of -$42.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- MBX Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$22.62M.
- MBX Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$20.21M.
- MBX Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$18.30M.
- MBX Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$21.54M.
- MBX Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$79.95M.
- MBX Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$54.68M.
- MBX Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$31.98M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$42.83M 10-Q · filed 2026-08-06 | -$61.13M derived: sum of 3 quarters · filed 2026-08-06 | -$82.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$20.21M 10-Q · filed 2026-05-07 | -$38.51M derived: sum of 2 quarters · filed 2026-05-07 | -$60.05M derived: sum of 3 quarters · filed 2026-05-07 | -$77.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$18.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$39.84M derived: sum of 2 quarters · filed 2026-03-12 | -$57.27M derived: sum of 3 quarters · filed 2026-08-06 | -$79.95M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$21.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$38.97M derived: sum of 2 quarters · filed 2026-08-06 | -$61.65M 10-Q · filed 2025-11-06 | -$77.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$17.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$40.11M 10-Q · filed 2026-08-06 | -$56.15M derived: sum of 3 quarters · filed 2026-08-06 | -$70.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$22.68M 10-Q · filed 2026-05-07 | -$38.72M derived: sum of 2 quarters · filed 2026-05-07 | -$53.38M derived: sum of 3 quarters · filed 2026-05-07 | -$66.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$16.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$30.70M derived: sum of 2 quarters · filed 2026-03-12 | -$43.97M derived: sum of 3 quarters · filed 2026-03-12 | -$54.68M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$14.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$27.93M derived: sum of 2 quarters · filed 2025-11-06 | -$38.64M 10-Q · filed 2025-11-06 | -$49.79M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$13.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$23.98M 10-Q · filed 2025-08-07 | -$35.13M derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$10.71M 10-Q · filed 2025-05-12 | -$21.86M derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$11.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$31.98M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | -$20.83M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |